StocksFundsScreenerSectorsWatchlists
FUSN

FUSN - Fusion Pharmaceuticals Inc Stock Price, Fair Value and News

21.31USD-0.05 (-0.23%)Market Closed

Market Summary

FUSN
USD21.31-0.05
Market Closed
-0.23%

FUSN Stock Price

View Fullscreen

FUSN RSI Chart

FUSN Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

-19.06

Price/Sales (Trailing)

874.5

EV/EBITDA

-20.2

Price/Free Cashflow

-21.1

FUSN Price/Sales (Trailing)

FUSN Profitability

EBT Margin

-4550.77%

Return on Equity

-42.65%

Return on Assets

-33.2%

Free Cashflow Yield

-4.74%

FUSN Fundamentals

FUSN Revenue

Revenue (TTM)

2.1M

Rev. Growth (Yr)

392.66%

Rev. Growth (Qtr)

12.95%

FUSN Earnings

Earnings (TTM)

-94.9M

Earnings Growth (Yr)

-14.47%

Earnings Growth (Qtr)

-63.34%

Breaking Down FUSN Revenue

Last 7 days

0.0%

Last 30 days

124.3%

Last 90 days

136.5%

Trailing 12 Months

424.9%

How does FUSN drawdown profile look like?

FUSN Financial Health

Current Ratio

15.01

Debt/Equity

0.16

Debt/Cashflow

-2.35

FUSN Investor Care

Shares Dilution (1Y)

34.28%

Diluted EPS (TTM)

-1.46

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20234.0M6.3M8.5M2.1M
2022826.0K1.3M1.7M2.2M
2021000381.0K

Tracking the Latest Insider Buys and Sells of Fusion Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Aug 31, 2023
rawat mohit
acquired
-
-
12,843
president & cbo
Aug 31, 2023
leamon christopher p
acquired
-
-
11,957
chief scientific officer
Nov 11, 2022
khuong chau quang
acquired
100,181
2.38
42,093
-
Aug 11, 2022
gannon steven
bought
90,132
2.03
44,400
-
Apr 27, 2022
valliant john
sold
-27,201
6.03
-4,511
chief executive officer
Apr 26, 2022
valliant john
sold
-13,032
6.07
-2,147
chief executive officer
Apr 25, 2022
valliant john
sold
-12,277
6.03
-2,036
chief executive officer
Apr 21, 2022
valliant john
sold
-5,541
6.01
-922
chief executive officer
Apr 20, 2022
valliant john
sold
-2,209
6.02
-367
chief executive officer
Apr 13, 2022
valliant john
sold
-76,881
6.41
-11,994
chief executive officer

1–10 of 50

Which funds bought or sold FUSN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 10, 2024
Yarbrough Capital, LLC
unchanged
-
900,171
1,638,910
0.07%
Apr 05, 2024
GAMMA Investing LLC
new
-
554
554
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
new
-
290,838
290,838
-%
Feb 26, 2024
Privium Fund Management B.V.
new
-
1,173,690
1,173,690
0.33%
Feb 26, 2024
PERCEPTIVE ADVISORS LLC
unchanged
-
19,287,300
26,440,900
0.59%
Feb 15, 2024
SPHERA FUNDS MANAGEMENT LTD.
reduced
-19.84
6,911,920
10,433,000
1.68%
Feb 15, 2024
Pier Capital, LLC
new
-
2,663,040
2,663,040
0.38%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
270,349
270,349
-%
Feb 15, 2024
CHARTWELL INVESTMENT PARTNERS, LLC
new
-
480,000
480,000
0.02%
Feb 14, 2024
Squarepoint Ops LLC
new
-
122,595
122,595
-%

1–10 of 47

Are Funds Buying or Selling FUSN?

Are funds buying FUSN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own FUSN
No. of Funds

Unveiling Fusion Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 08, 2024
federated hermes, inc.
11%
95,000
SC 13G/A
Mar 25, 2024
federated hermes, inc.
12.65%
10,716,153
SC 13D
Mar 20, 2024
healthcap vii, l.p.
4.5%
3,807,247
SC 13D/A
Mar 07, 2024
healthcap vii, l.p.
5.3%
3,807,247
SC 13D/A
Feb 14, 2024
canada pension plan investment board
4.%
3,116,966
SC 13G/A
Feb 13, 2024
avidity partners management lp
8.1%
6,500,328
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 19, 2024
perceptive advisors llc
6.5%
4,737,194
SC 13G
Jan 18, 2024
federated hermes, inc.
15.03%
10,886,153
SC 13G/A
Dec 18, 2023
flynn james e
8.84%
6,401,000
SC 13G

Recent SEC filings of Fusion Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Apr 12, 2024
10-K/A
Annual Report
Apr 12, 2024
8-K/A
Current Report
Apr 10, 2024
PREM14A
PREM14A
Apr 09, 2024
8-K
Current Report
Apr 08, 2024
SC 13G/A
Major Ownership Report
Mar 25, 2024
SC 13D
13D - Major Acquisition
Mar 20, 2024
10-K
Annual Report
Mar 20, 2024
8-K
Current Report
Mar 20, 2024
S-8
Employee Benefits Plan
Mar 20, 2024
SC 13D/A
13D - Major Acquisition

Peers (Alternatives to Fusion Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.2B
6.8B
-1.24% -34.47%
-8.53
5.87
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.7B
1.8B
0.05% -28.38%
-42.48
10.23
76.23% 61.08%
17.4B
2.4B
8.82% -6.19%
103.82
7.19
15.42% 18.43%
12.1B
3.7B
-8.57% -28.49%
20.24
3.27
8.87% 75.42%
MID-CAP
6.2B
396.6M
-9.73% -34.59%
-11.81
15.74
425.83% 18.94%
4.7B
-
-4.69% 71.46%
-7.23
60.35
54.84% -34.79%
3.3B
270.6M
-0.99% 6.40%
-13.71
12.12
440.80% -27.84%
3.1B
240.7M
-13.54% -18.95%
-10.32
12.72
-1.03% -92.09%
2.8B
726.4M
-12.42% -7.51%
-46.06
3.89
40.45% 71.62%
SMALL-CAP
1.8B
398.2M
-8.48% -15.36%
25.1
4.5
85.90% -14.05%
599.0M
983.7M
-18.48% -55.04%
-1.1
0.61
-50.36% 17.16%
428.3M
881.7K
-13.30% 407.71%
-9.6
466.16
-77.61% -5.33%
257.8M
4.9M
-1.96% -2.22%
-1.91
52.97
-54.97% 51.72%
7.2M
2.1M
77.59% 88.99%
-0.26
2.14
-13.45% 66.37%

Fusion Pharmaceuticals Inc News

Latest updates
MarketBeat16 hours ago
The Wall Street Journal19 Mar 202407:00 am
InvestorPlace19 Mar 202407:00 am
TradingView19 Mar 202407:00 am

Fusion Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q2
Revenue-100.0%-2,818,0002,495,0001,921,0001,308,000572,000198,00083,000204,000325,000521,000
Operating Expenses32.2%28,275,00021,395,00026,747,00024,883,00024,557,00023,971,00019,857,00021,110,00018,147,00019,840,00027,788,000
  S&GA Expenses-100.0%-6,810,0007,753,0009,006,0006,950,0007,420,0007,781,0008,449,0006,336,0007,156,0006,642,000
  R&D Expenses41.6%20,647,00014,585,00018,994,00015,877,00017,607,00016,551,00012,076,00012,661,00011,811,00012,684,00021,146,000
EBITDA Margin-335.6%-42.62-9.78-13.45-21.51-40.31-47.06-59.40-99.88-210--
Interest Expenses0.5%1,192,0001,186,0001,150,0001,096,0001,203,500190,000-53,00083,00081,000107,00097,000
Income Taxes538.3%1,315,000-300,000-245,000-11,000-330,500-761,000-700,000-55,000-173,00048,00014,000
Earnings Before Taxes------24,957,000-24,774,000-19,754,000-19,964,000-17,409,000-19,381,000-26,839,000
EBT Margin-334.6%-45.51-10.47-14.21-22.37-41.39-47.73-60.20-101-213--
Net Income-63.3%-28,179,000-17,252,000-25,175,000-24,291,000-24,617,000-24,013,000-19,073,000-19,909,000-17,236,000-19,429,000-26,853,000
Net Income Margin-329.2%-45.89-10.69-15.58-23.00-40.54-46.75-59.52-101-212--
Free Cashflow-0.6%-19,428,000-19,312,000-20,294,000-26,658,000-20,314,000-21,847,000-17,691,000-15,566,000-16,865,000-21,670,000-17,516,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22019Q4
Assets12.8%28625326826721923822823625226828229731131232369.00
  Current Assets19.7%24320320822117921620720521220318523422829732067.00
    Cash Equivalents134.3%63.0027.0032.0054.0044.0010763.0061.0055.0040.0030.0043.0092.0025132167.00
  Net PPE-2.9%5.005.006.005.005.004.004.003.003.002.003.003.002.002.001.001.00
Liabilities-2.4%63.0065.0065.0066.0057.0055.0029.0021.0021.0022.0019.0018.0016.006.008.0010.00
  Current Liabilities-7.2%16.0017.0017.0017.0015.0013.0012.0012.0013.0014.009.008.0012.005.008.004.00
  Long Term Debt0.4%35.0035.0034.0034.0034.0034.0010.00---------
    LT Debt, Non Current-100.0%-35.0034.0034.0034.0034.0010.00---------
Shareholder's Equity18.0%222188203201162183199215231246264279295306315-
  Retained Earnings-8.1%-376-348-331-306-281-257-233-214-194-177-157-130-113-99.82-89.82-34.77
  Additional Paid-In Capital11.4%5995385355074454424334304264234214104084064051.00
Shares Outstanding15.3%80.0069.0069.0063.0045.0044.0043.0043.0043.0043.0043.00-----
Float---302---98.00---274---545-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q2
Cashflow From Operations4.8%-17,944-18,839-19,584-25,435-19,364-21,625-17,316-14,971-16,327-21,510-17,307-20,596-3,082-12,868-6,197-7,620---
  Share Based Compensation8.7%3,2552,9943,0463,1492,7782,6972,7362,6332,3662,3742,1451,7181,3431,241426358---
Cashflow From Investing-139.3%-5,24213,326-26,319-24,528-42,93337,2489,64119,13130,89632,2173,659-28,998-155,104-54,967-168-214---
Cashflow From Financing17538.7%57,85532824,30859,51513128,9059,9881,709-50.0057.0021013056.00-2,296257,8409,907---

FUSN Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]  
Total revenue$ 2,068$ 1,461
Type of Revenue [Extensible List]us-gaap:CollaborativeArrangementMemberus-gaap:CollaborativeArrangementMember
Operating expenses:  
Research and development$ 70,103$ 58,895
General and administrative31,19730,600
Total operating expenses101,30089,495
Loss from operations(99,232)(88,034)
Other income (expense):  
Interest income9,5262,161
Interest expense(5,166)(1,801)
Other income (expense), net762(1,775)
Total other income (expense), net5,122(1,415)
Loss before (provision) benefit for income taxes(94,110)(89,449)
Income tax (provision) benefit(787)1,837
Net loss(94,897)(87,612)
Unrealized (loss) gain on investments706(354)
Comprehensive loss$ (94,191)$ (87,966)
Net loss per share -basic$ (1.45)$ (2)
Net loss per share -diluted$ (1.45)$ (2)
Weighted-average common shares outstanding-basic65,611,92343,748,549
Weighted-average common shares outstanding-diluted65,611,92343,748,549

FUSN Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 61,456$ 43,861
Accounts receivable761
Short-term investments172,153127,013
Prepaid expenses and other current assets9,3107,609
Restricted cash469454
Total current assets243,395178,998
Property and equipment, net5,3044,631
Deferred tax assets3,9614,806
Restricted cash8491,018
Long-term investments13,73515,761
Operating lease right-of-use assets18,5925,684
Other non-current assets 8,166
Total assets285,836219,064
Current liabilities:  
Accounts payable1,8602,686
Accrued expenses and other current liabilities9,86410,605
Deferred revenue333333
Operating lease liabilities4,1631,443
Total current liabilities16,22015,067
Long-term debt, net of discount34,77534,233
Income taxes payable, net of current portion301299
Deferred revenue, net of current portion6672,667
Operating lease liabilities, net of current portion11,3934,577
Total liabilities63,35656,843
Commitments and contingencies (Note 15)
Shareholders’ equity:  
Common shares, no par value, unlimited shares authorized as of December 31, 2023 and 2022; 79,700,262 shares and 44,805,627 shares issued and outstanding as of December 31, 2023 and 2022, respectively
Additional paid-in capital599,002444,552
Accumulated other comprehensive income (loss)237(469)
Accumulated deficit(376,759)(281,862)
Total shareholders' equity222,480162,221
Total liabilities and shareholders’ equity$ 285,836$ 219,064
FUSN
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. Its lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers. The company has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.
 CEO
 WEBSITEhttps://fusionpharma.com
 INDUSTRYBiotechnology
 EMPLOYEES101

Fusion Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Fusion Pharmaceuticals Inc? What does FUSN stand for in stocks?

FUSN is the stock ticker symbol of Fusion Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Fusion Pharmaceuticals Inc (FUSN)?

As of Fri Apr 12 2024, market cap of Fusion Pharmaceuticals Inc is 1.8 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FUSN stock?

You can check FUSN's fair value in chart for subscribers.

What is the fair value of FUSN stock?

You can check FUSN's fair value in chart for subscribers. The fair value of Fusion Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Fusion Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FUSN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Fusion Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether FUSN is over valued or under valued. Whether Fusion Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Fusion Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FUSN.

What is Fusion Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 12 2024, FUSN's PE ratio (Price to Earnings) is -19.02 and Price to Sales (PS) ratio is 872.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FUSN PE ratio will change depending on the future growth rate expectations of investors.